In this model and in strong contrast to the immunocompetent mouse model, treatment of ID8-Trp53(−/−)Brca2(−/−) tumours with 25 or 50 mg/kgBW olaparib did not mediate a survival benefit (Fig. 2g). The gene discussed is BRCA2; the disease is neoplasm.